The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women
JAMAPublished 16 June 1999
Steven R. Cummings, Stephen Eckert, K A Krueger, D Grady, T.J. Powles, Jane A. Cauley
Citations1,876
SJR quartileQ1
SJR score5.35
SNIP10.71
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during 3 years of treatment with raloxifene, mainly in the United States and Europe.
Abstract
Among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during 3 years of treatment with raloxifene.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
JAMARandomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
6,229 Citations1998Stephen B. Hulley
Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.
NatureMolecular basis of agonism and antagonism in the oestrogen receptor
3,343 Citations1997A.M. Brzozowski, A.C.W. Pike +8 more
The crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17β-oestradiol, and the selective antagonist raloxifene provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties.
CA A Cancer Journal for CliniciansCancer statistics, 1998
2,384 Citations1998Sarah Landis, Thomas S. Murray +2 more
The Surveillance Research Program of the American Cancer Society's Department of Epidemiology and Surveillance reports its 32nd annual compilation of cancer incidence, mortality, and survival data for the United States and around the world.
PubMedPolychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
2,156 Citations1998C. Focan, S. M. Steinberg +225 more
New England Journal of MedicineEffects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
1,649 Citations1997Pierre D. Delmas, Nina H. Bjarnason +6 more
Daily therapy with raloxifene increases bone mineral density, lowers serum concentrations of total and low-density lipoprotein cholesterol, and does not stimulate the endometrium.
New England Journal of MedicineA Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors
1,471 Citations1989B. Fisher, Joe Costantino +19 more
Tamoxifen significantly reduced the rate of treatment failure at local and distant sites, tumors in the opposite breast, and the incidence of tumor recurrence after lumpectomy and breast irradiation and was attained with a low incidence of clinically appreciable toxic effects.
JNCI Journal of the National Cancer InstituteEndometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *
1,280 Citations1994B. Fisher, Joseph P. Costantino +5 more
Risk of endometrial cancer increases following tamoxifen therapy for invasive breast cancer; however, net benefit greatly outweighs risk, and tamoxIFen treatment for breast cancer should continue.
New England Journal of MedicineEffects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
1,138 Citations1992Richard R. Love, Richard B. Mazess +6 more
In postmenopausal women, treatment with tamoxifen is associated with preservation of the bone mineral density of the lumbar spine, and whether this favorable effect on bone mineraldensity is accompanied by a decrease in the risk of fractures remains to be determined.
Obstetrics and GynecologyHormone replacement therapy and endometrial cancer risk: A meta-analysis
957 Citations1995Deb Grady, Tebeb Gebretsadik +3 more
Endometrial cancer risk increases substantially with long duration of unopposed estrogen use, and this increased risk persists for several years after discontinuation of estrogen therapy, similar to the increased risk of developing the disease.
The LancetInterim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
886 Citations1998Trevor J. Powles, Rosalind A. Eeles +7 more
The authors have been unable to show any effect of tamoxifen on breast-cancer incidence in healthy women, contrary to the report from the NSABP-P1 study showing a 45% reduction inhealthy women given tamoxIFen versus placebo.
JNCI Journal of the National Cancer InstituteFive Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors
869 Citations1996Bernard Fisher, James J. Dignam +19 more
The outcome of patients in the B-14 trial through 10 years of follow-up indicated that tamoxifen therapy provided substantial benefit to patients with early stage disease, and questions arose about how long the observed benefit would persist.
The LancetPrevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women
770 Citations1998Umberto Veronesi, Patrick Maisonneuve +6 more
In this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent and it is essential to continue follow-up to quantify the long-term risks and benefits of tamxifen therapy.
JAMAEffects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women
696 Citations1998Brian W. Walsh
Raloxifene favorably alters biochemical markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein(a), and by increasing HDL2-C without raising triglycerides.
JNCI Journal of the National Cancer InstitutePlasma Sex Steroid Hormone Levels and Risk of Breast Cancer in Postmenopausal Women
685 Citations1998Susan E. Hankinson, Walter C. Willett +6 more
The data, in conjunction with past epidemiologic and animal studies, provide strong evidence for a causal relationship between postmenopausal estrogen levels and the risk of breast cancer.
JNCI Journal of the National Cancer InstituteProportion of Breast Cancer Cases in the United States Explained by Well-Established Risk Factors
662 Citations1995M. Patricia Madigan, Regina G. Ziegler +3 more
The RRs for most of these risk factors were modest, but their prevalence as a group was high, leading to estimates that suggest that a substantial proportion of breast cancer cases in the United States are explained by well-established risk factors.
JNCI Journal of the National Cancer InstituteA Prospective Study of Endogenous Estrogens and Breast Cancer in Postmenopausal Women
627 Citations1995Paolo Toniolo, Mortimer Levitz +6 more
Although estrogen levels appeared to fall within the conventional limits of normality in all women under study, those who subsequently developed breast cancer tended to show higher levels of estrone, total estradiol, and free estradiola, and a lower percent of estradio bound to sex hormone-binding globulin than women who remained free of cancer.
Journal of Clinical InvestigationRaloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
613 Citations1994Larry J. Black, Masahiko Sato +8 more
Raloxifene has promise as an agent with beneficial bone and cardiovascular effects in the absence of significant uterine effects, and ethynyl estradiol diverged dramatically from estrogen in its lack of significant estrogenic effects on uterine tissue.
PubMedDevelopment of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.
417 Citations1988M M Gottardis, V. Craig Jordan
Tumors growing with TAM contained double the estrogen receptor content of the estradiol-stimulated MCF-7 tumors that were not exposed to TAM, which may represent a form of TAM resistance, i.e., TAM dependence that may occur before hormone independence is exhibited.
Annals of Internal MedicineElevated Serum Estradiol and Testosterone Concentrations Are Associated with a High Risk for Breast Cancer
411 Citations1999Jane A. Cauley, Frances L. Lucas +4 more
The hypothesis that serum concentrations of estradiol and testosterone, measured an average of 3 years before the clinical diagnosis of breast cancer, are related to risk for breast cancer in women 65 years of age or older is tested.
Annals of Internal MedicineEffects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women
374 Citations1991Richard R. Love, Donald A. Wiebe +6 more
During 2 years of treatment, tamoxifen showed generally favorable effects on the lipid and lipoprotein profile of treated postmenopausal women, which may partially explain the decrease in adverse events and in mortality related to coronary heart disease seen in patients receiving adjuvant tamoxIFen treatment.
Annual Review of Public HealthEpidemiology and Prevention of Breast Cancer
362 Citations1996Jennifer L. Kelsey, Leslie Bernstein
Little can be done at present to reduce breast cancer risk through primary prevention, but secondary prevention by mammographic screening in women of age 50 and older reduces mortality from breast cancer.
PubMedAntitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
352 Citations1987Gottardis Mm, Jordan Vc
It is demonstrated that keoxifene is not as effective in its antitumor action as TAM in the NMU model of rat mammary carcinoma.
JNCI Journal of the National Cancer InstituteCardiac and Thromboembolic Morbidity Among Postmenopausal Women With Early Stage Breast Cancer in a Randomized Trial of Adjuvant Tamoxifen
333 Citations1993Lars Erik Rutqvist, Anders Mattsson for the Stockholm Breast Cancer Study Group
New England Journal of MedicineBone Mass and the Risk of Breast Cancer among Postmenopausal Women
292 Citations1997Yuqing Zhang, Douglas P. Kiel +7 more
Women in the highest quartile of bone mass are at higher risk for postmenopausal breast cancer than those in the lowest quartile, and the mechanisms underlying this relation are not understood, but cumulative exposure to estrogen may play a part.
JAMABone Mineral Density and Risk of Breast Cancer in Older Women
290 Citations1996Jane A. Cauley
The findings suggest a link between 2 of the most common conditions affecting a woman's health and identifying a common denominator for these conditions should substantially improve the understanding of their etiology and prevention.
The FASEB JournalRaloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats
287 Citations1996Masahiko Sato, Marian K. Rippy +1 more
Data point to advantages of Separate compounds in the management of bone, uterine, serum cholesterol, and adipose tissues after estrogen deficiency, and show that the benzothiophene raloxifene has potentially important advantages over estrogen, tamoxifen, or nafoxidine in the uterus.
BMJCardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial
278 Citations1995C. McDonald, Freda E Alexander +3 more
The results provide further evidence that tamoxifen reduces the risk of myocardial infarction and thromboembolic events should be carefully monitored in trials of tamoxIFen, particularly those of prophylactic treatment, in which tamox ifen is given to healthy women.
Proceedings of the National Academy of SciencesMolecular determinants of tissue selectivity in estrogen receptor modulators
243 Citations1997Timothy A. Grese, James P. Sluka +11 more
Structural differences between raloxifene and tamoxifen may influence the conformations of their respective receptor/ligand complexes, thereby affecting which estrogen-responsive genes are modulated in various tissues, indicating that differences in tissue selective actions among benzothiophene and triarylethylene estrogen receptor modulators can be ascribed to discrete ligand conformations.
Diabetes CareEffect of Postmenopausal Hormone Therapy on Glucose and Insulin Concentrations
238 Citations1998Mark A. Espeland, Patricia E. Hogan +6 more
The impact of hormone therapy on insulin and glucose depended on baseline levels of fasting insulin and 1-h glucose (P < 0.05), but the treatment effects on carbohydrate metabolism appeared to be consistent across participant subgroups formed by lifestyle, clinical, and demographic characteristics.
JNCI Journal of the National Cancer InstituteAcquired Tamoxifen Resistance: Correlation With Reduced Breast Tumor Levels of Tamoxifen and Isomerization of Trans-4-Hydroxytamoxifen
235 Citations1991C. Kent Osborne, Ester B. Coronado +3 more
Metabolic tolerance, as manifested by alterations in cellular concentrations of tamoxifen and its metabolites, may be one mechanism for acquired tamoxIFen resistance in breast cancer.
PubMedRelation of prediagnostic serum estrogen and androgen levels to breast cancer risk.
218 Citations1996Joanne F. Dorgan, Christopher Longcope +8 more
The hypothesis that prediagnostic serum estrogens and androgens are related to the subsequent diagnosis of breast cancer in postmenopausal women is supported.
JAMAResource Utilization in Liver Transplantation<SUBTITLE>Effects of Patient Characteristics and Clinical Practice</SUBTITLE>
199 Citations1999Jonathan Showstack
Recipients who were older, had alcoholic liver disease, or were severely ill were the most expensive to treat; this suggests that organ allocation criteria may affect transplant costs.
Annals of OncologyOriginal article: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
173 Citations1992Anthony Howell, David Dodwell +2 more
WR are demonstrable after cessation of tamoxifen and norethisterone acetate with durations of response similar to those found with additive therapy, particularly in soft tissues.
JNCI Journal of the National Cancer InstituteChemoprevention of Mammary Carcinogenesis in the Rat: Combined Use of Raloxifene and 9-cis-Retinoic Acid
171 Citations1996Mario A. Anzano, Christopher W. Peer +8 more
The combination of 9cRA and raloxifene, which has a high binding affinity for the estrogen receptor and a low level of estrogenic activity and does not promote growth of uterine epithelium, was evaluated for its chemopreventive activity in the well-accepted rat model of breast cancer induced by the carcinogen nitrosomethylurea.
Journal of Surgical OncologyRates of growth of human neoplasms: Part II
163 Citations1996John S. Spratt, John S. Spratt +3 more
JNCI Journal of the National Cancer InstituteCoronary Heart Disease Mortality and Adjuvant Tamoxifen Therapy
152 Citations1997Joseph P. Costantino, James J. Dignam +3 more
The findings of the B-14 trial are consistent with the findings from the Scottish and the Swedish trials, suggesting that tamoxifen treatment reduces coronary heart disease among patients with breast cancer.
The LancetIs tamoxifen effective in prevention of breast cancer?
97 Citations1998Kathleen I. Pritchard
PubMedPostmenopausal endometrial fluid collections revisited: look at the doughnut rather than the hole.
73 Citations1994Steven R. Goldstein
Normal atrophic postmenopausal endometrium in association with cervical stenosis can produce endometrial fluid collections, seen easily on vaginal probe ultrasound, and sampling is not necessary.
SurgeryThe influence of clinical variables on hospital costs after orthotopic liver transplantation
60 Citations1999James F. Whiting, Jill Martin +2 more
Length of stay is the most important determinant of costs after OLTx, and Rational strategies to design cost-effective protocols after OLtx will require further studies to truly define the cost of various morbidities and outcomes after OLx.
EndocrinologyStimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins.
56 Citations1996D. Kleinman, Michael Karas +6 more
Examination of the involvement of the IGF system in the tamoxifen-stimulated growth of Ishikawa endometrial cancer cells by quantitating the IGF-I receptors and their phosphorylation, as well as membrane associated and secreted IGF-binding proteins (IGFBPs) suggests a molecular mechanism that accounts for the uterotropic effects that are seen with tamoxIFen therapy.
PubMedSocioeconomic aspects of hepatic transplantation.
54 Citations1987Jesse W. Williams, Santiago Vera +1 more
It is concluded that hepatic transplantation restores high-quality, useful life to patients with endstage liver disease in a predictable and cost-effective manner.
Ultrasound in Obstetrics and GynecologyEndometrial fluid accumulation in asymptomatic postmenopausal women
38 Citations1996Maarit Vuento, Jouko Pirhonen +5 more
Postmenopausal endometrial fluid accumulation was considered in the past to be related to cancer of the genital organs, but its prevalence and association with cervical stricture, use of hormone replacement therapy andendometrial pathology were evaluated.
MaturitasTransvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen
37 Citations1996F. P. H. L. J. Dijkhuizen, Hans A.M. Brölmann +4 more
The data indicate that tamoxifen stimulates the uterine body and endometrium and that the ultrasonographic endometrial appearance during tamoxIFen therapy may be misleading and that a high percentage of false-positive results occur.